The Readout Loud

On this week’s episode of "The Readout LOUD": the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug research. Plus, drug safety concerns weigh on some of the biggest companies in the sector.

For years, it was widely believed that a deeper understanding of genetics was going to speed the development of newer and better medicines for patients with heart disease. But then came this year’s American Heart Association meeting, which was dominated by presentations of clinical trials that showed no benefit whatsoever for two drugs long thought to be genetically validated.

Joining us to help sort out this cardiovascular conundrum and what it might portend for the future of drug research is our colleague and senior medical writer Matthew Herper.

We also chat about drug safety concerns weighing on Vertex Pharmaceuticals and Novartis, and Alnylam’s stock price tumbling on growth concerns.

How will the midterm results affect drug pricing policy? What is the fate of the Food and Drug Administration? And why are women traveling to fertility clinics abroad?

On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on our Washington correspondent Daniel Payne to chat about the massive midterm victory for Democrats and what it means for health and medicine.

We also bring on our colleague Megan Molteni to discuss her investigation into a network of clinics that have advertised fertility success with a questionable and expensive genetic procedure.

What is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna's mRNA cancer vaccine? And what are the next big advances in oncology?

On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on our colleague Andrew Joseph to discuss the latest cancer data presented at the annual meeting of the European Society for Medical Oncology. We also make an announcement about the podcast.

Helen Branswell was a renowned infectious disease reporter who earned the respect and admiration of experts and public health officials with her authoritative, prescient reporting on the flu, polio, Ebola and the Covid-19 pandemic.

This week’s episode of “The Readout LOUD” is dedicated to Helen, who died last week due to complications of cancer. We speak with her colleagues at STAT, family and public health leaders about her work and her legacy.

Longevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work?

On this week's episode of “The Readout LOUD,” STAT's biotech podcast, we bring on STAT reporter Sarah Todd to discuss the booming industry of longevity health and her visit to one of the many longevity clinics popping up in major hospitals across the country.